Research Papers:

This article has been corrected. Correction in: Oncotarget. 2020; 11:2586-2586.

Nucleolin represses transcription of the androgen receptor gene through a G-quadruplex

Cindy K. Miranti, Sara Moore, Yongeun Kim, Venkateshwar Reddy Chappeta, Kui Wu, Biswanath De, Vijay Gokhale, Laurence H. Hurley and Elsa M. Reyes-Reyes _

PDF  |  Full Text  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2020; 11:1758-1776. https://doi.org/10.18632/oncotarget.27589

Metrics: PDF 852 views  |   Full Text 1388 views  |   ?  


Cindy K. Miranti1,2, Sara Moore3, Yongeun Kim4, Venkateshwar Reddy Chappeta4, Kui Wu4, Biswanath De4, Vijay Gokhale5, Laurence H. Hurley1,4,5 and Elsa M. Reyes-Reyes1,2,3

1 University of Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA

2 Department of Cellular and Molecular Medicine, Tucson, AZ 85724, USA

3 University of Arizona College of Medicine, Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Tucson, AZ 85724, USA

4 College of Pharmacy, University of Arizona, Tucson, AZ 85724, USA

5 BIO5 Institute, University of Arizona, Tucson, AZ 85724, USA

Correspondence to:

Elsa M. Reyes-Reyes,email: emreye01@email.arizona.edu

Keywords: prostate cancer; androgen receptor; nucleolin; gene repression; G-quadruplex

Received: October 29, 2019     Accepted: April 14, 2020     Published: May 12, 2020


The androgen receptor (AR) is a major driver of prostate cancer development and progression. Men who develop advanced prostate cancer often have long-term cancer control when treated with androgen-deprivation therapies (ADT). Still, their disease inevitably becomes resistant to ADT and progresses to castration-resistant prostate cancer (CRPC). ADT involves potent competitive AR antagonists and androgen synthesis inhibitors. Resistance to these types of treatments emerges, primarily through the maintenance of AR signaling by ligand-independent activation mechanisms. There is a need to find better ways to block AR to overcome CRPC. In the findings reported here, we demonstrate that the nuclear scaffold protein, nucleolin (NCL), suppresses the expression of AR. NCL binds to a G-rich region in the AR promoter that forms a G-quadruplex (G4) structure. Binding of NCL to this G4-element is required for NCL to suppress AR expression, specifically in AR-expressing tumor cells. Compounds that stabilize G4 structures require NCL to associate with the G4-element of the AR promoter in order to decrease AR expression. A newly discovered G4 compound that suppresses AR expression demonstrates selective killing of AR-expressing tumor cells, including CRPC lines. Our findings raise the significant possibility that G4-stabilizing drugs can be used to increase NCL transcriptional repressor activity to block AR expression in prostate cancer. Our studies contribute to a clearer understanding of the mechanisms that control AR expression, which could be exploited to overcome CRPC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 27589